Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)
NCT05332002Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Jul 2022
- Primary completion
- Feb 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in gastroesophageal junction cancer, sponsored by Rutgers University. Started Jul 2022; status: recruiting.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05332002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332002.